Table 3.

Potential therapeutic strategies targeting AGEs in cardiovascular disease

Therapeutic strategy	Specific targets/compounds	Mechanism of action	Preclinical/clinical studies	Limitations/challenges
Inhibiting AGE formation and accumulation	Aminoguanidine, Pyridoxamine	Blocking the formation of AGEs by trapping reactive carbonyl species	Preclinical, limited clinical trials	Side effects, limited efficacy
	Alagebrium (ALT-711)	Breaks AGE crosslinks, reduces AGE accumulation	Preclinical, Phase II clinical trials	Safety concerns, Incomplete efficacy
Blocking AGE-receptor interactions	Soluble RAGE, Anti-RAGE antibodies	Competitively inhibits binding of AGEs to RAGE, preventing receptor activation	Preclinical, Phase I clinical trials	Limited efficacy, Immunogenicity
	AGER1/OST-48 overexpression	Enhances AGER1-mediated suppression of RAGE signaling	Preclinical	Challenges in gene therapy delivery
Targeting downstream signaling pathways	Inhibition of NF-κB, MAPK, PI3K/Akt	Reduces AGE-induced pro-inflammatory responses and oxidative stress	Preclinical	Potential off-target effects
	Inhibition of NADPH oxidase	Reduces AGE-induced reactive oxygen species (ROS) production	Preclinical	Potential off-target effects
Antioxidant and anti-inflammatory therapies	N-Acetylcysteine, Vitamin E, Curcumin	Scavenges free radicals and reduces inflammation, indirectly targeting AGE pathways	Preclinical, Some clinical studies	Limited efficacy, Need for specificity